December 21, 2023

Dear Community,

We are writing to inform you that Ionis has initiated a Phase 1/2a clinical trial of ION717 called “PrProfile” (pronounced ‘profile’) (NCT06153966). PrProfile is a global, multi-center, early-phase clinical trial designed to examine the safety, tolerability, pharmacokinetics, and pharmacodynamics of ION717 in individuals diagnosed with symptomatic prion disease. ION717 is an investigational drug designed to lower the amount of prion protein in the brain. Additional information, including key eligibility criteria, trial site locations, and contact information, is available here.

Individual sites will be ready to screen people for potential enrollment into the trial on a rolling basis. Ionis is working with planned trial investigators and their institutions to open enrollment in a limited number of sites across multiple different countries as quickly as possible. We will update the clinicaltrials.gov page as new trial sites are added.

In PrProfile, we aim to enroll approximately 56 people in the early stage of symptomatic prion disease. All individuals enrolled in PrProfile will receive ION717 and placebo during the trial’s 24-week double-blind treatment period. The order of the doses will be assigned randomly. The trial is “double-blinded” meaning neither the trial participants nor site investigators/staff know which doses are ION717 and which doses are placebo.

Individuals interested in participating in PrProfile should discuss it with their doctor. To learn more about the purpose of clinical trials, visit the US Health and Human Services website for educational fact sheets and videos. Individuals may call +1-844-221-3587 or email PrionDisease@clinicaltrialmedia.com for information about open trial site locations. Please note that Ionis is not involved in enrollment decisions.

We are grateful for our partnership with the prion disease community since the earliest days of our prion disease research program. We will continue to provide updates on this program at key milestones.

Sincerely,
Ionis ION717 Team

Below is additional information you may find helpful:

**Who can a person contact for more information about this clinical trial?**

Individuals interested in participating in the Phase 1/2a clinical trial of ION717, called PrProfile, should discuss it with their doctor. Individuals may also call +1-844-221-3587 or write to PrionDisease@clinicaltrialmedia.com for information about open trial site locations.
Why are only people in the early stage of prion disease eligible to participate in this trial?

Enrolling people at a similar disease stage can allow for more efficient clinical trials. This is because minimizing variability in the enrolled population makes it more feasible to identify effects of the investigational drug. In addition, for a clinical trial to be successful, it is essential that trial participants complete the trial. Participation in a clinical trial is a big commitment of time and energy. This clinical trial requires periodic travel to the trial site and participation in many assessments. Based on these considerations, only people at an early stage of symptomatic prion disease will be enrolled in PrProfile.

Why are healthy individuals with genetic variants that put them at risk for developing prion disease not eligible to participate in this clinical trial, and do you plan to include them in the future?

PrProfile was designed with input and collaboration from scientists, clinicians, regulators, and the prion disease community. The decision to focus this trial on individuals diagnosed with symptomatic prion disease is based on our belief that this pathway will enable the quickest opportunity to evaluate whether ION717 will help people with prion disease. The information from this study and our additional research will help determine next steps in the program.

Must a person be a citizen or resident in the country in which the trial site is in order to participate in the trial? (aka cross-border/cross-country participation)?

For this study, Ionis does not require that a person be a citizen or resident of the country the study site in which they are accepted is located. However, each research site may have its own policies for receiving individuals from other countries. These policies are independent of Ionis. Prospective study participants should speak directly with their preferred study site to identify any restrictions or challenges based on the institution’s policies.

Is there a way to receive ION717 outside the clinical trial, such as for people not eligible for this clinical trial?

Evaluation of the safety and efficacy of ION717 in clinical trials is essential to establishing whether ION717 can help people diagnosed with prion disease. For this reason, ION717 is not available outside this clinical trial at this time. We are working diligently to conduct the clinical trials necessary to evaluate ION717 in individuals with prion disease. For additional information about Ionis’ expanded access policy, click here.

How long will it take to complete PrProfile?

PrProfile will conclude after all participants complete all study procedures and study visits. Ionis will utilize Clinicaltrials.gov to communicate updates regarding the study’s status and anticipated completion dates. However, the study’s timeline largely depends on how long it takes to complete enrollment. Therefore, the dates that will be posted are subject to change.

—

The CJD Foundation (US) and CJD International Support Alliance are community resources that provide education and support to those affected by prion disease.

For more information about Ionis, visit www.ionispharma.com or email padvocacy@ionisph.com.